Cargando…

Meta-analysis of the effect of PGM on survival prognosis of tumor patients

OBJECTIVE: A systematic evaluation of the impact of phosphoglucose translocase PGM on the survival prognosis of tumor patients was conducted to understand its impact on tumors so as to improve the quality of survival and to find effective therapeutic targets for tumor patients. METHODS: The followin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhewen, Bai, Jian, Shen, Shuangting, Zhu, Chunmei, Zhou, Yunfeng, Zhang, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760796/
https://www.ncbi.nlm.nih.gov/pubmed/36544711
http://dx.doi.org/10.3389/fonc.2022.1060372
_version_ 1784852559911976960
author Zheng, Zhewen
Bai, Jian
Shen, Shuangting
Zhu, Chunmei
Zhou, Yunfeng
Zhang, Xue
author_facet Zheng, Zhewen
Bai, Jian
Shen, Shuangting
Zhu, Chunmei
Zhou, Yunfeng
Zhang, Xue
author_sort Zheng, Zhewen
collection PubMed
description OBJECTIVE: A systematic evaluation of the impact of phosphoglucose translocase PGM on the survival prognosis of tumor patients was conducted to understand its impact on tumors so as to improve the quality of survival and to find effective therapeutic targets for tumor patients. METHODS: The following were searched in the databases China National Knowledge Infrastructure (CNKI), Wanfang, Wipu, PubMed, EMBASE, ScienceDirect, Web of Science, and Cochrane Library: “PGM1”, “PGM2”, “PGM3”, “PGM4”, and “PGM5” as Chinese keywords and “PGM1”, “PGM2”, “PGM3”, “PGM4”, “PGM5”, “PGM1 cancer”, “PGM2 cancer”, “PGM3 cancer”, “PGM4 cancer”, “PGM5 cancer”, and “phosphoglucomutase”. Relevant studies published from the database establishment to April 2022 were collected. Studies that met the inclusion criteria were extracted and evaluated for quality with reference to the Cochrane 5.1.0 systematic evaluation method, and quality assessment was performed using RevMan 5.3 software. RESULTS: The final results of nine articles and 10 studies with a total of 3,806 patients were included, including 272 patients in the PGM1 group, 541 patients in the PGM2 group, 1,775 patients in the PGM3 group, and 1,585 patients in the PGM5 group. Results of the meta-analysis: after determining the results of the nine articles, it was found that the difference was statistically significant with a p-value <0.05 (hazard ratio (HR) = 0.89, 95% CI 0.69–1.09, p = 0.000). To find the sources of heterogeneity, the remaining eight papers were tested after removing the highly sensitive literature, and the results showed I(2) = 26.5%, p < 0.001, a statistically significant difference. The HR for high expression of PGM1 and PGM2 and PGM5 was <1, while the HR for high expression of PGM3 was >1. CONCLUSION: Although PGM1, PGM2, PGM3, and PGM5 are enzymes of the same family, their effects on tumors are different. High expression of PGM1, PGM2, and PGM5 can effectively prolong the overall survival of patients. In contrast, high expression of PGM3 reduced the overall survival of patients. This study of PGM family enzymes can assist in subsequent tumor diagnosis, treatment, and prognostic assessment.
format Online
Article
Text
id pubmed-9760796
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97607962022-12-20 Meta-analysis of the effect of PGM on survival prognosis of tumor patients Zheng, Zhewen Bai, Jian Shen, Shuangting Zhu, Chunmei Zhou, Yunfeng Zhang, Xue Front Oncol Oncology OBJECTIVE: A systematic evaluation of the impact of phosphoglucose translocase PGM on the survival prognosis of tumor patients was conducted to understand its impact on tumors so as to improve the quality of survival and to find effective therapeutic targets for tumor patients. METHODS: The following were searched in the databases China National Knowledge Infrastructure (CNKI), Wanfang, Wipu, PubMed, EMBASE, ScienceDirect, Web of Science, and Cochrane Library: “PGM1”, “PGM2”, “PGM3”, “PGM4”, and “PGM5” as Chinese keywords and “PGM1”, “PGM2”, “PGM3”, “PGM4”, “PGM5”, “PGM1 cancer”, “PGM2 cancer”, “PGM3 cancer”, “PGM4 cancer”, “PGM5 cancer”, and “phosphoglucomutase”. Relevant studies published from the database establishment to April 2022 were collected. Studies that met the inclusion criteria were extracted and evaluated for quality with reference to the Cochrane 5.1.0 systematic evaluation method, and quality assessment was performed using RevMan 5.3 software. RESULTS: The final results of nine articles and 10 studies with a total of 3,806 patients were included, including 272 patients in the PGM1 group, 541 patients in the PGM2 group, 1,775 patients in the PGM3 group, and 1,585 patients in the PGM5 group. Results of the meta-analysis: after determining the results of the nine articles, it was found that the difference was statistically significant with a p-value <0.05 (hazard ratio (HR) = 0.89, 95% CI 0.69–1.09, p = 0.000). To find the sources of heterogeneity, the remaining eight papers were tested after removing the highly sensitive literature, and the results showed I(2) = 26.5%, p < 0.001, a statistically significant difference. The HR for high expression of PGM1 and PGM2 and PGM5 was <1, while the HR for high expression of PGM3 was >1. CONCLUSION: Although PGM1, PGM2, PGM3, and PGM5 are enzymes of the same family, their effects on tumors are different. High expression of PGM1, PGM2, and PGM5 can effectively prolong the overall survival of patients. In contrast, high expression of PGM3 reduced the overall survival of patients. This study of PGM family enzymes can assist in subsequent tumor diagnosis, treatment, and prognostic assessment. Frontiers Media S.A. 2022-12-05 /pmc/articles/PMC9760796/ /pubmed/36544711 http://dx.doi.org/10.3389/fonc.2022.1060372 Text en Copyright © 2022 Zheng, Bai, Shen, Zhu, Zhou and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zheng, Zhewen
Bai, Jian
Shen, Shuangting
Zhu, Chunmei
Zhou, Yunfeng
Zhang, Xue
Meta-analysis of the effect of PGM on survival prognosis of tumor patients
title Meta-analysis of the effect of PGM on survival prognosis of tumor patients
title_full Meta-analysis of the effect of PGM on survival prognosis of tumor patients
title_fullStr Meta-analysis of the effect of PGM on survival prognosis of tumor patients
title_full_unstemmed Meta-analysis of the effect of PGM on survival prognosis of tumor patients
title_short Meta-analysis of the effect of PGM on survival prognosis of tumor patients
title_sort meta-analysis of the effect of pgm on survival prognosis of tumor patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760796/
https://www.ncbi.nlm.nih.gov/pubmed/36544711
http://dx.doi.org/10.3389/fonc.2022.1060372
work_keys_str_mv AT zhengzhewen metaanalysisoftheeffectofpgmonsurvivalprognosisoftumorpatients
AT baijian metaanalysisoftheeffectofpgmonsurvivalprognosisoftumorpatients
AT shenshuangting metaanalysisoftheeffectofpgmonsurvivalprognosisoftumorpatients
AT zhuchunmei metaanalysisoftheeffectofpgmonsurvivalprognosisoftumorpatients
AT zhouyunfeng metaanalysisoftheeffectofpgmonsurvivalprognosisoftumorpatients
AT zhangxue metaanalysisoftheeffectofpgmonsurvivalprognosisoftumorpatients